<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000725</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 013</org_study_id>
    <secondary_id>10989</secondary_id>
    <nct_id>NCT00000725</nct_id>
  </id_info>
  <brief_title>A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma</brief_title>
  <official_title>A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's&#xD;
      sarcoma with zidovudine (AZT) and two kinds of interferon alpha. The two kinds are interferon&#xD;
      alpha (IFN-A) and interferon alpha-2A (recombinant) (IFN-A2A). To define the pharmacokinetics&#xD;
      of both AZT and IFN-A or IFN-A2A when given in combination; to define the maximum tolerated&#xD;
      dose of each drug in combination and to define doses to be used in Phase II trials. AZT has&#xD;
      been found to inhibit both the in vitro (in test tube) and cell killing effects of HIV, and&#xD;
      both interferons (IFN-A and IFN-A2A) have shown antiviral and antitumor effect in Kaposi's&#xD;
      sarcoma. It is reasonable to assume that a synergistic effect and enhanced antitumor response&#xD;
      may be seen with combination therapy. A study to evaluate the safety and efficacy of AZT in&#xD;
      combination with IFN-A or IFN-A2A is warranted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AZT has been found to inhibit both the in vitro (in test tube) and cell killing effects of&#xD;
      HIV, and both interferons (IFN-A and IFN-A2A) have shown antiviral and antitumor effect in&#xD;
      Kaposi's sarcoma. It is reasonable to assume that a synergistic effect and enhanced antitumor&#xD;
      response may be seen with combination therapy. A study to evaluate the safety and efficacy of&#xD;
      AZT in combination with IFN-A or IFN-A2A is warranted.&#xD;
&#xD;
      Patients are randomized to receive IFN-A or IFN-A2A (given by intramuscular injection) and&#xD;
      combined with AZT (taken orally) daily for 8 weeks. Study stops when maximum tolerated dose&#xD;
      (MTD) is reached. Two cohorts of 4 patients enter each dose level. Patients do not enter into&#xD;
      the next dose level until all patients have completed 3 weeks of treatment. AZT will escalate&#xD;
      only if there is no unacceptable toxicity (grade 2 in = or &gt; 3 patients or &gt; grade 2 in any&#xD;
      patient), subsequent increases in IFN-A or IFN-A2A will be permitted, but the AZT dose will&#xD;
      remain fixed. The MTD for a given IFN-A or IFN-A2A dose level is defined as grade 2 toxicity&#xD;
      (grade 3 for hemoglobin, neutrophil count, or SGOT) in 4 of the 6 patients. Patients have&#xD;
      blood drawn every week and their general health is evaluated. Pharmacokinetic studies will be&#xD;
      done on days 1, 21, and 24. Patients tolerating the combination may be continued on the same&#xD;
      dose level for 1 year except if patient has reached complete remission for = or &gt; 90 days,&#xD;
      IFN-A or IFN-A2A will decrease to 3 times a week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 1990</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>56</enrollment>
  <condition>Sarcoma, Kaposi</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-2a</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alfa-n1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients must have biopsy-proven AIDS-associated Kaposi's sarcoma.&#xD;
&#xD;
          -  Evidence of HIV infection as manifested by a positive antibody test.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active drug or alcohol abuse.&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Excluded are patients with:&#xD;
&#xD;
          -  Active opportunistic infections requiring ongoing therapy.&#xD;
&#xD;
          -  Excluded within 90 days of study entry:&#xD;
&#xD;
          -  Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including a history of myocardial infarction&#xD;
             or arrhythmia.&#xD;
&#xD;
          -  Concurrent neoplasms other than basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Known hypersensitivity to polymycin B or neomycin.&#xD;
&#xD;
        Excluded are patients with:&#xD;
&#xD;
          -  Active opportunistic infections requiring ongoing therapy.&#xD;
&#xD;
          -  Excluded within 90 days of study entry:&#xD;
&#xD;
          -  Must be off therapy for Pneumocystis carinii pneumonia (PCP) unless recovered.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including a history of myocardial infarction&#xD;
             or arrhythmia.&#xD;
&#xD;
          -  Concurrent neoplasms other than basal cell carcinoma of the skin.&#xD;
&#xD;
          -  Known hypersensitivity to polymycin B or neomycin.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Interferon.&#xD;
&#xD;
          -  Zidovudine (AZT).&#xD;
&#xD;
          -  Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Any biologic modifiers, corticosteroids, cytotoxic chemotherapeutic agents.&#xD;
&#xD;
          -  Other drugs which can cause neutropenia or significant nephrotoxicity.&#xD;
&#xD;
          -  Rifampin or rifampin derivatives, or systemic anti-infectives.&#xD;
&#xD;
          -  Excluded within 90 days of study entry:&#xD;
&#xD;
          -  Other antiviral agents.&#xD;
&#xD;
          -  A history of Pneumocystis carinii pneumonia (PCP) completed treatment.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded within 30 days of study entry:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fischl MA</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fischl MA, Uttamchandani RB, Resnick L, Agarwal R, Fletcher MA, Patrone-Reese J, Dearmas L, Chidekel J, McCann M, Myers M. A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma. J Acquir Immune Defic Syndr (1988). 1991;4(1):1-10.</citation>
    <PMID>1670585</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interferon Alfa-2a</keyword>
  <keyword>Sarcoma, Kaposi</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>Interferon Type I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

